RxDoctor Payments Data

Zarine Ter-Poghosyan, MD

Family Medicine · Burbank, CANPI 1114102993

Payments from drug & device makers

$22,326in general payments, 2019–2025

Across 999 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AbbVie$3K
  • AstraZeneca$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • GSK$979
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$1,2005%
  • Travel & lodging$50%
  • Food & beverage$20,97294%
  • Education$1491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)135$3,365
AbbVie(2 entities)141$2,676
AstraZeneca62$1,363
Biohaven Pharmaceuticals, Inc.5$1,288
Lilly USA, LLC56$1,129
GSK43$979
Bayer27$922
Sanofi-aventis U.S. LLC41$881
Boehringer Ingelheim36$844
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC62$791
Novo Nordisk33$606
Novartis31$598
Pfizer44$582
Johnson & Johnson9$559
Ironwood Pharmaceuticals, Inc29$530
Takeda Pharmaceuticals U.S.A., Inc.22$411
Sumitomo Pharma America, Inc.18$398
Astellas Pharma US Inc18$386
Amarin Pharma, Inc.16$327
Otsuka America Pharmaceutical, Inc.12$290
Almatica Pharma LLC10$239
Scilex Pharmaceuticals Inc.11$219
Hikma Pharmaceuticals USA11$188
Sunovion Pharmaceuticals Inc.13$180
Kvk-tech, Inc.12$176
Mylan Specialty L.p.8$174
Merck8$149
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$138
Ardelyx, Inc.5$138
Digestive Care, Inc.2$127
Regeneron Healthcare Solutions, Inc.4$125
Exact Sciences6$118
Axsome Therapeutics, Inc.5$116
Lundbeck LLC5$116
Idorsia Pharmaceuticals US Inc5$93
Biohaven Pharmaceutical Holding Company Ltd.4$93
Kowa Pharmaceuticals America, Inc.3$86
Esperion Therapeutics, Inc.4$85
E.r. Squibb & Sons, L.L.C.5$83
Phathom Pharmaceuticals, Inc.3$79
Sanofi2$75
Xeris Pharmaceuticals, Inc.3$62
Nestle Healthcare Nutrition Inc.2$49
Avanir Pharmaceuticals, Inc.2$42
Redhill Biopharma Inc.2$37
Mannkind Corporation2$35
Merz North America, Inc.1$32
Radius Health, Inc.1$27
Tonix Medicines, Inc.1$26
Tanabe Pharma America, Inc.1$26
Tersera Therapeutics LLC1$25
Abbott1$25
Biogen1$24
Vivus LLC1$23
Verona Pharma, Inc.1$23
Zyla Life Sciences, Inc.1$22
Azurity Pharmaceuticals, Inc.1$22
QOL Medical, LLC1$22
Sun Pharmaceutical Industries Inc.1$19
Phadia US Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,326 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$469,212
Medicare patients
621
Services billed
25,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase288$313,355
LinzessLinaclotide549$310,080
MounjaroTirzepatide271$288,850
Metformin Er GastricMetformin Hcl226$283,081
OzempicSemaglutide287$276,243
VascepaIcosapent Ethyl630$203,432
FarxigaDapagliflozin Propanediol285$182,171
JardianceEmpagliflozin279$171,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter218$139,739
EliquisApixaban189$121,714
Breo ElliptaFluticasone/Vilanterol295$119,912
TezspireTezepelumab-Ekko22$114,041
Diclofenac Sodium666$113,915
Diclofenac Potassium76$112,764
TrulicityDulaglutide97$98,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Ubrelvy$2,676$700,278914 claims
Lilly USA, LLCMounjaro, Trulicity$1,129$387,823368 claims
AstraZenecaFarxiga, Tezspire, Breztri Aerosphere$1,363$377,066433 claims
Novo NordiskOzempic, Rybelsus$606$371,882382 claims
Boehringer IngelheimJardiance, Synjardy, Jentadueto$844$314,677511 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$979$305,690614 claims
PfizerEliquis, Nurtec Odt$582$161,023229 claims
MerckJanumet, Januvia$149$137,204228 claims
AmgenProlia, Evenity (2 Syringes)$3,365$100,92652 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$411$97,299177 claims
Sumitomo Pharma America, Inc.Gemtesa$398$48,70097 claims
Astellas Pharma US IncMyrbetriq$386$48,112102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →